pharma · Asthma · Type 2 Diabetes
AstraZeneca
AstraZeneca patent portfolio — 2 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 1
- Drugs
- 61
- Patents
- 2
AstraZeneca patents
2 pharmaceutical patents indexed for AstraZeneca. 0 expire within 24 months.
AstraZeneca has 2 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
WO 2026109729
COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSPC) DÉFICIENT EN PTEN
granted -
US 20260097057
COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS
granted
Frequently asked questions
How many patents does AstraZeneca have?
2 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do AstraZeneca patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.